Oxlumo
(Lumasiran)RNA therapy
Alnylam PharmaceuticalsOxlumo is one of 5 small molecule programs targeting Primary Hyperoxaluria Type 1. It is currently in development.
1
Indications
8
Total Trials
1
Active Trials
4
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Primary Hyperoxaluria Type 1
#DrugCompanyPhaseTrials
1Diacomit
BBiocodex
Phase 3
DCR-PHXC
DDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 2
ABO-101
AArbor Biotechnologies
Phase 2
Rivfloza
Novo NordiskPreclinical
Oxlumo
Alnylam PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Primary Hyperoxaluria Type 16 trials
Show 3 more trials
Kidney Stone1 trial
Haemodialysis1 trial
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
Recruiting·—·Phase 2·NCT06225544·50 enrolled
Regulatory
FDA Approval Timeline[4]
Nov 23, 2020
OXLUMO
NDA NDA214103
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lumasiran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Oxlumo. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy[2]
- Company